Autism Society records most keynote and concurrent sessions at their annual conferences. You can see and hear those recordings by purchasing full online access, or individual recordings.
Registered attendees have free access, please select the button above for the file you would like to access.
Purchase AccessThe main focus of the session, however, will be on evaluating tiers of evidence. While it is well-recognized that the randomized clinical trial (RCT) is the gold standard in clinical treatment outcome research, there are almost no such studies of autism treatment. Instead, educators as well as parents must rely on quasi-experimental studies (such as Lovaas's original 1987 work on DTT) but may lack expertise in understanding how experimental design features matter in considering the relevance of results of quasi-experimental studies or other designs such as single case studies or clinical reports. The goal of the presentation will be for the participant to better understand how, in the absence of much empirical data, an educator or parent can rely on developmental theory, behavioral theory, and neurobiological studies to extrapolated about what may constitute justifiable treatments. As providers of autism treatment, we need to rely on different kinds of evidence, but also need to understand whether treatments are supported by sound theoretical foundations, if not empirically-demonstrated effectiveness.
Increasingly, autism treatment is a marketplace' with stakeholders vending' specific treatments in which they have an economic investment. Often there is neither behavioral or biological science backing assertions behind treatment efficacy. This presentation will aim to create a more informed consumer' of these services and provide criteria and strategies for evaluating new treatments as they occur.
Content Area: Education
Bryna Siegel
Professor, Child & Adolescent Psychiatry
University of California, San Francisco